Funapide
Funapide is a novel analgesic under development by Xenon Pharmaceuticals for the treatment of a variety of chronic pain conditions, including osteoarthritis, neuropathic pain, postherpetic neuralgia, and erythromelalgia, as well as dental pain. It acts as a small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker. Funapide was evaluated in humans in both oral and topical formulations, and as of July 2014, had reached phase IIb clinical trials. Development of the drug was discontinued in 2022.